Concentra Biosciences
As of the edition of 20 October 2026, Concentra Biosciences runs 27 drugs, 5 of them marketed; it is on route A at 11 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 8 company names in this family.
- Allakos Inc.: acquired in 2025; successor Concentra Biosciences, LLC
- CARGO Therapeutics: acquired in 2025; successor Concentra Biosciences, LLC
- iTeos Therapeutics: acquired in 2025; successor Concentra Biosciences, LLC
- Elevation Oncology: acquired
- IGM Biosciences, Inc.: acquired
- Jounce Therapeutics, Inc.: acquired
- Kronos Bio: acquired
Drugs by status
| Status | Count |
|---|---|
| Marketed | 5 |
| Active | 1 |
| Went quiet | 1 |
| Stopped | 13 |
| Status not established | 7 |
| Total | 27 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Lidocaine | none listed | 2 |
| Suxamethonium | none listed | 0 |
| Aminosalicylic acid | none listed | 0 |
| Ceforanide | none listed | 0 |
| Nalidixic acid | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 11 targets, route B at 0 targets.
All 11 rows on route A or B
In the product11 company-target rows on route A or B; 8 are not shown here, and no score is.
See all 11 targets where Concentra Biosciences needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 21 trials led
- Immune system: 20 trials led
- Blood and lymph: 13 trials led